Response rates in the efficacy-evaluable population
| Response rates . | Efficacy-evaluable population (n = 147) . |
|---|---|
| CR∗ or CRh | |
| n (%) [95% CI] | 51 (35) [27.0-43.0] |
| Median time to CR/CRh, mo (range) | 1.9 (0.9-5.6) |
| CR∗ | |
| n (%) [95% CI] | 47 (32) [24.5-40.2] |
| Median time to CR, months (range) | 2.8 (0.9-7.4) |
| Overall response | |
| N (%) [95% CI] | 71 (48) [40.0-56.7] |
| Median time to first overall response, mo (range) | 1.9 (0.9-10.2) |
| Best overall response, n (%) | |
| CR∗ | 47 (32) |
| CRh | 4 (3) |
| CRi | 15 (10) |
| PR | 3 (2) |
| MLFS | 2 (1) |
| SD† | 42 (29) |
| Progressive disease | 10 (7) |
| Not evaluable/not done | 6 (4) / 18 (12) |
| Response rates . | Efficacy-evaluable population (n = 147) . |
|---|---|
| CR∗ or CRh | |
| n (%) [95% CI] | 51 (35) [27.0-43.0] |
| Median time to CR/CRh, mo (range) | 1.9 (0.9-5.6) |
| CR∗ | |
| n (%) [95% CI] | 47 (32) [24.5-40.2] |
| Median time to CR, months (range) | 2.8 (0.9-7.4) |
| Overall response | |
| N (%) [95% CI] | 71 (48) [40.0-56.7] |
| Median time to first overall response, mo (range) | 1.9 (0.9-10.2) |
| Best overall response, n (%) | |
| CR∗ | 47 (32) |
| CRh | 4 (3) |
| CRi | 15 (10) |
| PR | 3 (2) |
| MLFS | 2 (1) |
| SD† | 42 (29) |
| Progressive disease | 10 (7) |
| Not evaluable/not done | 6 (4) / 18 (12) |
CRi, CR with incomplete blood count recovery; PR, partial remission; SD, stable disease (failure to achieve at least a PR but not meeting criteria for progressive disease. SD for a period of ≥8 weeks indicates clinical benefit).
Includes patients with CR, complete cytogenetic remission, and complete molecular remission.
Includes 3 patients considered to have clinical benefit by the treating physician and 2 patients considered to have resistant but stable disease.